In a bid to amp up its radiopharmaceuticals pipeline, Pentixapharm has chosen to...
Despite having exited the COVID-19 vaccine market this year, pharma giant AstraZ...
Sanofi and Regeneron gained approval from the European Union for expanded use of...
Eisai will terminate a partnership on a dual-action lung and ovarian cancer medi...
A freshly created coalition consisting of major Big Pharma players has been set ...
The current and future landscape of respiratory syncytial virus (RSV) vaccinatio...
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was...
While Novo Nordisk have remained focused on the rare blood disorders market, the...
AstraZeneca’s chief product in the cancer treatment segment, Imfinzi, has not me...
In a study conducted on women and men with heart failure compared to a placebo, ...
UK-based GSK and U.S-based Pfizer first began their RSV race when it came to win...
It seems like GLP-1 giants Novo Nordisk and Eli Lilly are locked in a fierce bat...
An interim analysis of Merck’s TrilynX study, involving patients with unresected...
Hikma, a generics manufacturer headquartered in London, has reached an agreement...
Japanese pharmaceutical company Takeda has granted rights to Indian firms Cipla ...
An experimental medication has demonstrated potential as an aid for certain peop...
